ADC Landscape
Mersana
B7-H4 · Breast cancer
Phase 1Antibody–Drug Conjugates
Target
B7-H4
Payload
Auristatin (DolaLock)
Payload class
Auristatin
Linker
Cleavable
Indication
Breast cancer
Phase
Phase 1
Overview
Proprietary Dolasynthen platform with a controlled-bystander auristatin. B7-H4 is an under-contested target — an early-stage wedge in solid tumors.
Technology
Mersana works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.